in clinical trials, and we report the digestive symptoms subscale because we hypothesized it would be affected in patients with abdominal pain related to malabsorption or distal intestinal obstruction syndrome.
Hospital Anxiety and Depression Scale:
The Hospital Anxiety and Depression Scale (HADS) is a 14-question assessment that measures anxiety and depression in the medical setting. 18 The HADS has been used extensively for . 20 years to assess psychologic distress in patients in a medical setting.
Clinical Outcomes: Electronic chart review was performed by one investigator, blinded to the patient survey responses, to assess acute pulmonary exacerbations (exacerbations were defi ned by the need for IV antibiotics in the setting of increased respiratory symptoms), FEV 1 , and deaths for the 12 months following survey completion. Mean FEV 1 was defi ned as the mean of the highest FEV 1 per quarter in the year the survey was completed.
Data Analysis: Summary statistics were represented as mean Ϯ SD or median with interquartile range. Bivariate analyses were performed using Wilcoxon log rank tests, Kruskal-Wallis tests, and Spearman correlations. Logistic regression models and Cox proportional hazard models were used to analyze clinical outcomes, including exacerbations and death. Multivariable models included factors found to be signifi cant on univariate analysis or felt to be clinically important. A P value , .05 was considered statistically signifi cant. Hazard ratios and ORs are presented with 95% CIs. Statistical analyses were performed with Stata statistical software, release 10 (StataCorp; College Station, Texas).
Results
Of the 137 adult patients contacted to complete this survey, 83 patients responded (61% response rate). Although the majority of patients were white with a higher socioeconomic status, some respondents had a lower socioeconomic status and the group was diverse with respect to disease severity (median FEV 1 , 63.6%; range, 27.6%-134.0% predicted). The median age of patients in this study was 29.3 years, ranging from 19 to 71 years ( Table 1 ) .
We found that pain was common in our adult population with CF, because an overwhelming majority (82%) reported pain within the past 30 days; more than one-half (56%) had talked to their doctors about pain, and many used over-the-counter medications or complementary approaches for pain control ( Table 2 ) . Twenty-seven percent of patients reported chronic pain, defi ned as pain most of the time for Ն 6 months during the prior year. Of those that reported pain, 41.9% described their pain as moderate to severe and about one-third had pain rated at Ն 5 out of 10 ( Fig 1 ) . The most common location of pain was the head (63.5%), followed by the sinuses (54%), back, chest, and abdomen. Knee pain was reported by 29.7% of participants, 18.9% reported wrist pain, and 5% had fi nger pain ( Fig 2 ) .
We were unable to fi nd any patient characteristics that were associated with the presence of pain.
have been a handful of studies showing that pain is indeed prevalent in patients with CF [4] [5] [6] [7] [8] and that its importance may be underestimated. 6 Although there is evidence that pain is common in patients with CF, there are few data regarding the factors associated with pain or, more importantly, the effects of pain on clinical outcomes. It has been shown that pain does negatively impact the quality of life (QOL) in children with CF, 9, 10 and there is a single study suggesting an association between pain and shortened survival. 11 However, there is a paucity of studies showing that pain affects QOL in adults, 5, 12 and, moreover, no studies have examined the associations between psychologic distress and pain. We sought to determine the prevalence and location of pain, the effects of pain on QOL and mood, and its impact on clinical outcomes, including death. 
Materials and Methods

Questionnaires
Pain Inventory: The Brief Pain Inventory (BPI) is an assessment of pain that was originally developed for cancer patients to evaluate pain severity and to determine if pain interfered with daily life. 13 It has since been validated in patients without cancer. 14 The BPI asks patients if they have had pain in the past week and if they have had pain most days for the past 6 months, and asks them to qualify their pain on a scale of 0 to 10, 10 being pain "as bad as it could be." The BPI also asks patients on a scale of 0 to 10, 10 being "completely interferes," how much pain interferes with aspects of their life, including general activity, mood, relationships, sleep, and social activities. As was done in previous studies using the BPI, 15 we made a composite pain score, which included the mean of the lowest pain and average pain in the previous 7 days. We also performed analyses using average pain in the last 7 days and overall worst pain, and obtained similar results. Therefore, unless otherwise specifi ed, the results presented refl ect the composite pain score.
Pain Catastrophizing Scale: The Pain Catastrophizing Scale is a 13-question assessment with three different categories: rumination, magnifi cation, and helplessness. 16 The assessment evaluates the emotional response to pain, and describes how likely an individual is to respond negatively to pain.
CF Questionnaire-Revised:
The Cystic Fibrosis Quality of Life Scale-Revised (CFQ-R) is a 44-question, CF-specifi c, validated scale that measures health-related QOL 17 on 12 generic and disease-specifi c scales. We report the physical functioning and role subscales because they closely parallel the two subscales in the 36-Item Short Form Health Survey. We also report the respiratory subscale because it has been used frequently as an outcome tions persisted after adjusting for FEV 1 and age (OR 5 1.65; P 5 .038; 95% CI, 1.03-2.64). For this model, pain on the composite scale was coded as yes or no. The relationship between pain and worse clinical outcomes was examined using various measures of pain, with similar results (data not shown), suggesting a robustness of the fi ndings. Five patients died during follow-up, and the risk of death was higher in patients with higher average pain scores (HR 5 2.28; P 5 .008; 95% CI, 1.2-4.2)). Given the small number of deaths, we did not attempt to adjust for possible confounding variables.
QOL, Anxiety, and Depression
Using the CFQ-R, we found that patients with any pain on the composite pain scale had worse QOL. Specifi cally, the presence of pain was signifi cantly associated with worse scores on the respiratory subscale ( P 5 .008) and the digestion subscale ( P 5 .01) ( Table 3 ) . There was no association between pain and the CFQ-R Physical subscale ( P 5 .35 by Wilcoxon rank sum). However, those patients with pain did have signifi cantly worse scores on the role subscale of the CFQ-R ( P 5 .005). Patients reported that pain frequently interfered with general activities (41.9%), mood (56.8%), and work (47.3%). Patients with pain had higher scores on the pain catastrophizing scale (17.1 vs 22.1; P 5 .005).
Symptoms of depression and anxiety were more common among patients with pain. Depression and anxiety scores were signifi cantly higher in patients with pain in the past 7 days ( Table 3 ) , and were significantly correlated with increased levels of a composite pain score (depression r 5 0.43, P 5 .0003; anxiety r 5 0.31, P 5 .008).
We performed subgroup analyses looking at the association between the particular locations of pain and QOL, anxiety, and depression. We did not assess the association of specifi c pain locations with clinical outcomes because the sample size was relatively small in these subgroups. Head pain (which is a combination of both headache and sinus pain, the two most common locations of pain in this study) was associated with anxiety ( P 5 .05) but not depression. Chest pain was signifi cantly associated with anxiety ( P 5 .008), depression ( P 5 .007), and decreased QOL as measured by the CFQ-R respiratory subscale ( P 5 .001), role ( P 5 .001), and physical ( P 5 .005). Back pain was associated with anxiety ( P 5 .003) but not depression. Patients with back pain did have lower scores on the respiratory subscale ( P 5 .007) and emotion subscale ( P 5 .003). Abdominal pain was associated with depression ( P 5 .05) but not anxiety and, as expected, was associated with lower scores on the digestive subscale ( P , .001).
Specifi cally, FEV 1 and gender were not signifi cantly associated with the presence of pain, although there was a trend for patients who reported pain in the previous 7 days to be older (mean age, 34.6 vs 29.7 years; P 5 .06).
Effects of Pain on Clinical Outcomes
The risk of pulmonary exacerbations treated with IV antibiotics was increased in patients who reported pain on the composite pain scale. Neither gender ( P 5 .73) nor age ( P 5 .71) nor income ( P 5 .15) were associated with increased risk of exacerbations, whereas the risk of exacerbations was associated with lower FEV 1 (OR 5 0.96; P 5 .002; 95% CI, 0.94-0.99). This indicates that for every 1% increase in FEV 1 , the risk of pulmonary exacerbation decreased by 4%. The association between pain and pulmonary exacerba- that the risk of having a pulmonary exacerbation was increased with higher levels of pain, and, even more notable, the risk of death was higher in patients with higher average pain scores. The literature on pain and clinical outcomes in patients with CF is scarce, although one study from Abbott and colleagues 11 found a similar link between pain and survival in CF.
That study used the 36-Item Short Form Health Survey and found that the only symptom associated with shortened survival was pain. There are many speculations as to why pain may be associated with poor clinical outcomes. We conjecture that pain may lead to decreased mechanical airway clearance because either patients are in too much pain to participate in airway clearance activities or the treatments exacerbate their pain, which can worsen current infections and promote new ones. Pain may also be a marker of increased infl ammation and "disease activity" and, therefore, may indicate patients who are at risk of more rapid disease progression. These results suggest that patients with pain may be in need of more aggressive therapy aimed at treating the CF lung disease and other complications. Alternatively, pain may occur more commonly in "sicker" patients who have greater levels of disability. However, we did not fi nd an association between lower FEV 1 and pain, which makes the latter explanation less likely. Our study underscores the importance of pain in CF patients with CF. Three studies, 5, 10, 12 in addition to ours, have shown that pain in adults negatively impacts both life activities and QOL. We found that pain interfered with general activities (41.9%) and work (47.3%) at a higher rate than in the study of Sermet-Gaudelus et al , 10 in which only 21% of the 110 participants reported that pain caused absenteeism from work. Additionally, the majority of our study participants reported that pain affected their mood. The results from the HADS questionnaire likely refl ect the impact on mood because we demonstrate that depression and anxiety scores were significantly higher in patients with pain. Depression and chronic pain are tied closely together, 19 although it is diffi cult to sort out a temporal or causal relationship in our study because pain and depression were assessed at the same time point. It has been shown that depression is prevalent in patients with chronic pain. 20 These high anxiety and depression scores portend a poor prognosis for these patients because studies have shown that patients with depression and chronic diseases have worse outcomes. 21 The subgroup analyses of specifi c pain locations provide evidence of the internal validity of our results. Patients with abdominal pain reported lower scores on the digestive subscale of the CFQ-R, whereas those with chest pain had lower respiratory QOL scores. It is worth noting that patients with back pain
Discussion
This study confi rmed that pain is widespread in adult patients with CF and is clinically important. Pain interferes with daily activities and QOL and, most notably, is associated with an increased risk of acute pulmonary exacerbations and death. To the best of our knowledge, this is the fi rst study to demonstrate this association and it underscores the need for more studies in this patient population.
Although it was shown previously that pain is common in CF populations, its signifi cance has been underappreciated and underestimated. We showed More work is needed to help elucidate the potential mechanisms linking pain to exacerbations and shortened survival. In addition, this study begs the question, how should pain be treated in this population? The alleviation of pain in these patients is no small feat. In our study, 45% of patients relied on chiropracty, yoga, and massage for pain relief. In one small (n 5 97) study of pediatric patients with CF, 77% of patients used some method of complementary medicine. 22 As complementary medical techniques become more main stream, we anticipate that more of this population will at least attempt alternative therapies for pain relief.
In addition to complementary medical techniques, analgesics such as nonsteroidal antiinfl ammatory drugs (NSAIDs) and opioids can be used but, unfortunately, neither are harmless medications. Ibuprofen has been shown to improve outcomes in the CF population; however, the benefi t has been demonstrated only in the pediatric age group. A randomized trial of high-dose ibuprofen, published in 1995, showed an 89% decrease in the rate of decline in patients aged 5 to 13 years old. 23 The authors chose a high dose of ibuprofen because earlier studies had shown that lower doses of ibuprofen may actually increase infl ammation. A larger study published in 2007 using the CF registry showed a . 60% reduction in FEV 1 decline over 2 to 7 years in patients aged 6 to 17 years old. 24 This study also showed an increased risk of GI bleeding. In the present study, 58% of patients took ibuprofen, but not high-dose ibuprofen comparable to the Konstan et al 23 study. Our study was not powered to adequately assess the impact of specifi c medications on outcomes and it is, therefore, possible that low-dose ibuprofen could have paradoxically increased infl ammation and led to worse outcomes and could partly explain the association we found between pain and pulmonary exacerbations. If high-dose ibuprofen can be shown to relieve pain effectively and safely in these patients, it may be a good drug to use because of its possible positive effects on lung function. However, NSAID use does not come without risks because there are serious side effects associated with NSAIDs. The increased risk of renal toxicity, in the setting of concomitant aminoglycoside use, makes NSAIDs a poor choice for pain control during an exacerbation. When not in exacerbation, NSAIDs are a relatively good choice of pain control for patients; however, long-term use may be precluded by potential deleterious effects on the kidneys and GI tract. Opioids also are not ideal in this population for several reasons. First, they can cause constipation and thus increase the risk of distal intestinal obstruction syndrome. Second, opioids can lead to respiratory depression. Lastly, opioids suppress cough, which could lead to impaired airway clearance had lower respiratory QOL. Patients with pain related to lung pathology may have diffi culty differentiating musculoskeletal back pain from pain in the back related to a pulmonary process. It is not clear what signifi cance to attach to the variable associations among anxiety, depression, and certain pain locations (ie, some locations were associated with anxiety and not depression, whereas other locations were associated with depression and not anxiety). It may be that certain locations of pain cause patients to worry more and lead to higher levels of anxiety symptoms, whereas other locations of pain interfere more with daily activities and lead to more depressive symptoms.
There are several limitations to our study. We had a 61% response rate to our survey and, therefore, are at risk of selection bias. There may be differences in pain and outcomes in the patients who chose not to complete the survey. This, as well as the fact that all patients came from one large academic center, may decrease the generalizability of this study. However, our patient population was fairly diverse, with a wide age span and varied disease severity. Because patients were asked about pain in the 30 days and 7 days prior to the survey, there could be misclassifi cation because the patients may have had inadequate and/or imprecise recall of their pain. However, the BPI is a commonly used instrument and has been shown to yield valid results in numerous populations. We recognize that the BPI and the other scales we used have not been validated in the CF population; however, the BPI has been shown to be valid in a variety of noncancer populations. Because pain, anxiety, and depression were all assessed at the same time, we cannot determine causal links among these entities. Lastly, this is a single center study; therefore, our fi ndings should be replicated in a large multicenter study because our current data are taken from just one large institution.
This study has yielded important information about the clinical signifi cance of pain in adults with CF. Future studies should include expanding this work into the pediatric population to see if children and adolescents with CF have similar sequelae from pain. in CF. Our study did not look at whether treatment of pain improved outcomes; thus, it will be interesting to determine in future studies if effective pain treatment improves clinical outcomes. We have confi rmed that pain is prevalent in the adult CF patient population; moreover, we have shown novel data that pain increases the risk of severe pulmonary exacerbations and death. Currently, pain was not thought of as either a marker of disease severity or a contributor of disease progression. However, we have shown that pain is indeed negatively associated with clinical outcomes and should not only be assessed in this patient population but also duly treated. Perhaps something as seemingly simple as effectively treating pain in our patients could have a dramatic impact on their risk of exacerbations and death.
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